拉米夫定联合阿德福韦酯与恩替卡韦单药治疗HBeAg阳性慢性乙型肝炎疗效观察被引量：13

Comparison of efficacy and safety of entecavir to lamivudine and adefovir combination in treatment of patients with HBeAg-positive hepatitis B

下载PDF

导出

摘要目的观察拉米夫定联合阿德福韦酯与恩替卡韦单药治疗HBeAg阳性慢性乙型肝炎96周的疗效,以探讨理想的初始抗病毒治疗方案。方法选择HBeAg阳性慢性乙型肝炎患者86例,随机分为单药治疗组44例和联合治疗组42例,分别给予恩替卡韦或拉米夫定联合阿德福韦酯治疗,观察96 w的疗效。结果在96 w治疗结束时,恩替卡韦治疗患者ALT复常率、血清HBV DNA阴转率和HBeAg阴转率分别为95.5%、84.1%和38.6%,而联合治疗患者则分别为88.1%、42.9%(P<0.05)和31.0%;两组均无患者血清HBsAg转阴。两组均未发生严重的不良反应。结论应用恩替卡韦单药治疗对于HBeAg阳性慢性乙型肝炎初始抗病毒治疗在96 w时的病毒学应答率显著优于拉米夫定和阿德福韦酯联合治疗。

作者张淑娥

机构地区河南省焦作市第三人民医院三病区

出处《实用肝脏病杂志》 CAS 2014年第5期527-528,共2页 Journal of Practical Hepatology

关键词慢性乙型肝炎拉米夫定阿德福韦酯恩替卡韦治疗 Hepatitis B Enteeavir Lamivudine Adefovir Therapy

分类号 R512.62 [医药卫生—内科学]

引文网络
相关文献

参考文献10

1Liaw YF. On-treatment outcome prediction and adjustment during chronic hepatitis B therapy:now and future Antivir Ther,2009,14:13-22.
2Ahn SH,Kweon YO,Paik SW,et al. Telbivudine in combina- tine with adefovir versus adefovir monotherapy in HBeAg-positive,lamivudine-resistant chronic hepatitis B. Hepatol Int,2011,12:448-451.
3伍思国,李耀才,杨智娟,陈瑞圣,易聪桓,戚子惠.拉米夫定联合抗乙肝转移因子和强肝胶囊治疗慢性乙型肝炎的疗效观察[J].实用肝脏病杂志,2006,9(2):84-86. 被引量：10
4慢性乙型肝炎防治指南(2010年版)[J].实用肝脏病杂志,2011,14(2):81-89. 被引量：436
5斯崇文.对当前慢性乙型肝炎抗病毒治疗的看法[J].中华传染病杂志,2005,23(2):73-74. 被引量：55
6Liaw YF,Leung N, Kao JH, et al. Asian-pacific statement on the management of chronic haepatitis B:a 2008 update. Liver Int,2008,2(3):263-283.
7Zoulim F,Buti M, Lok AS. Antiviral-resistant heaptitis B virus:Can we prevent the monster from growing. J Viral Heoat,2007,14(supp 1 ):S29-36.
8朱宝剑.阿德福韦酯联合拉米夫定治疗拉米夫定耐药慢性乙型肝炎患者的临床研究[J].中国医师进修杂志,2010,33(4):22-24. 被引量：17
9Seifer M,Hamatake RK,Colonno RJ,et al. In vitro inhibition of hepadnavims polymerases by the triphosphates of BMS-200d75 and lobucavir. Antimicrob Agents Chemother,1998,42:3200-3208.
10Sherman M,Yurdayin C, Sollano J, et al Entecavir for treatment of lamivudine-refractory,HBeAg-positive chronic hepatitis B. Gastroenterology, 2006,130: 2039.

二级参考文献18

1Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
2Yeon JE,Yoo W,Hong SP.阿德福韦双酯治疗拉米夫定耐药的慢性乙肝患者时出现的耐药问题[J].中国处方药,2006(3):23-23. 被引量：81
3Lok ASF, McMahon BJ. AASLD practice guidline: Chronic hepatitis B: Update of recommendations. Hepatology, 2004,39:857-861.
4Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on management of chronic hepatitis B: an update.Hepatology, 2003, 18:239-245.
5Yuen MF, Wang KH,Sablon E, et al. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological,and clinical aspects. Hepatology, 2004, 39 : 1694-1701.
6Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatits B. Hepatology, 2003, 37:748-755.
7Lee KM, Cho SW, Kim SW, et al. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat, 2002, 9:208-212.
8van Numen AB, Hansen BE, Sub DJ, et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase, Gut2003,52:420-424.
9McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis, 2004,24 : 17-21.
10Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone and in combination with lamivudine in patients with lamivudine resistant chronic hepatitis B. Gastroneterology, 2004,126:91-101.